Physician profile
Christopher T Fahey
NPI 1306926415
$596.57
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $83.03 · 2021: $125 · 2022: $164 · 2023: $63.23 · 2024: $34.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.85 | 2021-2023 | |
| Lilly USA, LLC | $73.85 | 2020-2022 | |
| Genentech USA, INC. | $46.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $45.76 | 2020-2022 | |
| Glaxosmithkline, LLC. | $45.21 | 2019-2024 | Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $42.73 | 2022 | |
| Pfizer INC. | $33.48 | 2019-2021 | |
| Novo Nordisk INC | $33.38 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $30.87 | 2022 | |
| Eisai INC. | $24.92 | 2020 | |
| Bausch Health US, LLC | $24.44 | 2019 | |
| Seqirus USA INC | $23.49 | 2023 | Flucelvax Quadrivalent |
| Horizon Therapeutics Plc | $17.72 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.04 | 2019 | |
| Esperion Therapeutics, INC. | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.